Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tvardi Therapeutics, Inc.TVRD · Entity 7579 | VP, Chem, Mfg and Ctrls | April 17, 2025 | April 21, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tvardi Therapeutics, Inc.
Report date April 17, 2025 · Filed April 21, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.04 · Expires 2035-04-16 | Direct | 7,213 |
Reported balance
After 2025-04-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-04-17 · Grant · Acquired 7,213 · Balance 7,213 F1: 25% of the shares subject to the option shall vest on April 17, 2026, and the balance of the shares subject to the option shall vest in equal monthly installments over the following 36 months, subject to the Reporting Person's continuous service through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to the option shall vest on April 17, 2026, and the balance of the shares subject to the option shall vest in equal monthly installments over the following 36 months, subject to the Reporting Person's continuous service through each applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 17, 2025 Filed Apr 21, 2025 21:15 UTC | Tvardi Therapeutics, Inc. TVRD · Entity 7579 | GrantEmployee Stock Option (right to buy) · Derivative | 7,213 | $0.00 Strike: $17.04 | $0.00 |
DisclosureSEC source: 0001415889-25-011116 · form4-04212025_050423.xml · derivative · entry 1 Chen Yixin · CIK 0002064987 · VP, Chem, Mfg and Ctrls 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,213 Underlying: Common Stock · 7,213 shares Expires 2035-04-16 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on April 17, 2026, and the balance of the shares subject to the option shall vest in equal monthly installments over the following 36 months, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| April 15, 2025 Filed Apr 17, 2025 22:50 UTC | Tvardi Therapeutics, Inc. TVRD · Entity 7579 | GrantEmployee Stock Option (right to buy) · Derivative | 14,752 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001415889-25-010981 · form4-04172025_060411.xml · derivative · entry 1 Chen Yixin · CIK 0002064987 · VP, Chem, Mfg and Ctrls 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,752 Underlying: Common Stock · 14,752 shares Expires 2031-12-15 F2 · price: Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the "Merger"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each outstanding option to purchase shares of Legacy Tvardi common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc. F3 · price: Received in exchange for a stock option to acquire 110,000 shares of common stock of Tvardi Therapeutics, Inc. ("Legacy Tvardi") with the exercise price of $0.63 per share pursuant to an Agreement and Plan of Merger and reorganization by and among, the Issuer, CT Convergence Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub") and Legacy Tvardi, as amended (the "Merger Agreement"). F1 · derivative.exercise_date: 25% of the shares subject to the option vested on the one year anniversary of the vesting commencement date and the balance of the shares vested or will vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.